The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The use of subcutaneous natural ghrelin to treat cachexia (CC)-related symptom distress, nutritional intake (NI), and physical functioning: A two-step phase I/II study with an intrapatient dose escalation followed by maintenance treatment.
F. Strasser
No relevant relationships to disclose
D. Blum
No relevant relationships to disclose
R. Oberholzer
No relevant relationships to disclose
S. deWolf-Linder
No relevant relationships to disclose
C. Driessen
No relevant relationships to disclose
T. Cerny
No relevant relationships to disclose